By John 
In the healthcare industry, trust between medical professionals and device manufacturers should be grounded in product quality and patient outcomes not financial incentives. However, the case of Innovasis Inc. reveals how this trust was allegedly compromised through systematic kickback payments to spine surgeons. Settled in June 2024, the Innovasis lawsuit resulted in a $12 million settlement for violating the False Claims Act through illegal payments to physicians. The case, brought by whistleblower Robert Richardson, highlights ongoing concerns about corruption in the medical device industry and the mechanisms used to expose fraud.
Have you read our previously published blog – Ashcroft Capital Lawsuit: A Complete Research-Based Report
Background: What Is Innovasis?
Innovasis Inc., founded in 2004 and based in Salt Lake City, Utah, is a spinal implant device manufacturer specializing in bioactive PEEK (polyetheretherketone) implants infused with hydroxyapatite. The company became known in the orthopedic community for hosting the annual Spine Surgery Symposium, a prestigious conference attracting leading orthopedic and neurosurgeons nationwide. The symposium was held at Deer Valley, a luxury resort, positioning the company as an innovator in spine care technology.
Under the leadership of founder and President Brent Felix (an orthopedic surgeon) and his brother Garth Felix (Chief Financial Officer), Innovasis grew into a significant player in the spinal device market. The company’s products were used in procedures funded by Medicare and other federal healthcare programs. However, what appeared to be a successful medical device company was, according to federal investigators, built partly on a system of illegal payments designed to influence physician purchasing decisions.
The Core Allegations
The settlement resolved allegations that Innovasis systematically violated the Federal Anti-Kickback Statute from January 2014 through December 2022 a nine-year period. The scheme allegedly involved 17 orthopedic surgeons and neurosurgeons who received improper payments in exchange for using Innovasis spinal implants in patient procedures.
Forms of Improper Payments: The alleged kickbacks took multiple forms designed to appear legitimate while functioning as inducements. Consulting fees paid to surgeons far exceeded fair market value for actual services rendered. In some cases, surgeons received payments for consulting work that was never actually performed. Intellectual property acquisition and licensing fees were paid for technology that was never developed, marketed, or meaningfully pursued. Performance shares in Innovasis were distributed as incentives. These payments created an undisclosed financial relationship between the company and the surgeons.
Luxury Experiences as Incentives: Beyond direct payments, Innovasis allegedly used the annual Spine Surgery Symposium as a vehicle for kickbacks. The company covered first-class airfare, luxury accommodations, and premium meals for surgeons and their families. Attendees received Innovasis-branded ski jackets and other gifts. These expenses were presented as educational conference benefits but functioned as rewards for surgeons who chose Innovasis products in patient care.
Secret Payment Accounts: According to the whistleblower complaint, company executives maintained undisclosed “house accounts” used to make payments to referring physicians. These accounts were kept secret from most employees, suggesting intentional concealment of the payment arrangements.
Federal Healthcare Impact: The critical violation was that these procedures influenced by improper payments were billed to Medicare and other federal healthcare programs. This transformed what might have been seen as routine business relationships into violations of the False Claims Act, which prohibits submitting false claims to the government for reimbursement.
Timeline of Events
| Period | Key Events |
|---|---|
| 2004-2013 | Innovasis founded and operates in medical device market. Company builds reputation through Spine Surgery Symposium and product development. |
| 2014-2022 | Alleged kickback scheme operates. Improper payments made to 17 surgeons through consulting fees, IP payments, performance shares, and luxury experiences. Surgeons use Innovasis implants in Medicare-covered procedures. |
| May 2019 | Innovasis discovers compliance issues through internal audit. Board of Directors initiates voluntary self-disclosure to HHS Office of Inspector General under Self-Disclosure Protocol. Company engages healthcare law firm Hooper Lundy & Bookman to revamp compliance programs. |
| October 2019 | Former Regional Sales Director Robert Richardson files whistleblower lawsuit under False Claims Act qui tam provisions. Lawsuit alleges systematic kickback violations from 2014-2022. |
| 2019-2024 | Innovasis cooperates with government through self-disclosure protocol while defending against whistleblower lawsuit. Company implements revised compliance procedures and compliance training. |
| June 2024 | Innovasis Inc., Brent Felix, and Garth Felix agree to $12 million settlement. Whistleblower Robert Richardson receives $2.2 million. Settlement resolves all allegations without admission of wrongdoing. |
| 2024-2025 | Innovasis faces separate patent infringement lawsuit (RSB Spine LLC) with potential $50 million exposure. Company continues operations with enhanced compliance oversight. |
Company’s Response about Innovasis Lawsuit
Innovasis’s approach to the allegations reflected frustration with the whistleblower mechanism. The company stated: “Even though Innovasis self-reported in May 2019 and does not understand why a whistleblower should be rewarded after a company self-reports, it is in the company’s best interest to resolve this matter.”
The company argued that early self-disclosure should have provided legal protection or at least prevented the whistleblower from receiving a financial reward. Notably, the high-level employee responsible for executing most of the questionable agreements was not named as a defendant in the lawsuit, despite him having resigned during the internal audit. The company emphasized its commitment to advancing spine care and highlighted clinical data showing excellent outcomes from its bioactive implants on over 3,800 patients.
The Whistleblower and How the Case Emerged
Robert Richardson, a former Regional Sales Director for Innovasis, became suspicious of certain payment arrangements. The breakthrough came when Richardson received an angry voicemail from a surgeon asking where his $250,000 payment was for intellectual property that was never developed or marketed. The contract covered a two-year period for purported intellectual property that “did not lead to anything of substance,” according to the complaint.
Richardson’s position gave him direct knowledge of the company’s practices. His decision to file suit under the False Claims Act’s qui tam provisions. which allow private citizens to sue on behalf of the government proved significant. The qui tam mechanism incentivizes whistleblowers by allowing them to receive 15-30% of government recovery if the case succeeds. Richardson received approximately $2.2 million from the $12 million settlement, reflecting his crucial role in exposing the fraud.
Industry Impact and Lessons
The Innovasis case illuminates ongoing compliance challenges in the medical device industry. The case highlights the importance of healthcare companies implementing proper speaker program compliance, as the HHS Office of Inspector General issued a Special Fraud Alert in November 2020 warning that companies hosting or sponsoring speaker programs and healthcare practitioners who participate could face anti-kickback liability.
The settlement sends a clear message: self-disclosure, while helpful, does not guarantee immunity or eliminate whistleblower claims. Companies must not only report violations but demonstrate through restructured business practices that corruption will not recur. The case also underscores that seemingly legitimate business expenses consulting arrangements, conference sponsorships, luxury experiences—can constitute illegal kickbacks if they are tied to physician purchasing decisions.
Current Status
As of February 2026, Innovasis has completed its settlement and continues operating as a medical device manufacturer. However, the company faces additional legal exposure. Innovasis faces a separate patent infringement lawsuit from RSB Spine LLC regarding the Ax Stand-Alone ALIF System, with potential valuations of approximately $50 million related to bone-plate stabilization system technology used in spinal devices.
Conclusion
The Innovasis case demonstrates serious consequences of improper financial relationships in healthcare. For physicians, the settlement shows the government actively prosecutes arrangements where consulting fees or gifts are tied to purchasing decisions. Healthcare professionals must ensure payments are at fair market value and independent of clinical decisions. For device manufacturers, the $12 million settlement reinforces that compliance programs must be robust and transparent. Self-disclosure helps mitigate consequences but does not eliminate legal exposure. Companies must implement strong controls over physician payments and maintain transparent accounting. Ultimately, both healthcare professionals and manufacturers benefit from operating with integrity while avoiding fraud exposure and regulatory scrutiny.
Disclaimer: This article is based on publicly available information, DOJ press releases, and court documents as of February 2026. It is for informational purposes only and does not constitute legal advice. The settlement information reflects the final resolution of the alleged kickback claims. Consult qualified healthcare law professionals regarding compliance matters.